HOME >> MEDICINE >> NEWS
Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR

Philadelphia, PA., May 19, 2003 Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that a landmark analysis of studies comparing antidepressant treatments demonstrated that significantly more patients achieved remission (virtual elimination) of their depression symptoms, and resolution of both emotional and physical symptoms, when treated with EFFEXOR/EFFEXOR XR (venlafaxine HCl) than with commonly used selective serotonin reuptake inhibitors (SSRIs) or placebo. The analysis was presented in two poster presentations at the American Psychiatric Association's (APA) annual meeting in San Francisco.

The analysis compared EFFEXOR®/EFFEXOR XR to the SSRIs PAXIL® (paroxetine), PROZAC® (fluoxetine), ZOLOFT® (sertraline), LUVOX® (fluvoxamine), and CELEXA (citalopram) and comprised the entire worldwide dataset of Wyeth-sponsored registration and post-marketing, published and unpublished, SSRI-controlled clinical studies of EFFEXOR/EFFEXOR XR to date.

"Given the urgency to treat a patient to remission, these data reinforce EFFEXOR XR as a first-line therapy for depression," says Dr. Eric Hollander, Professor of Psychiatry and Director of Psychopharmacology at Mount Sinai School of Medicine in New York City. "This is important information for physicians as remission is a critical milestone in preventing symptom recurrence and depression relapse."

In one poster it was determined that EFFEXOR/EFFEXOR XR-treated patients had significantly higher remission rates than those treated with the studied SSRIs using standard evaluations including scoring seven or less on the 17-item Hamilton Rating Scale for Depression (HAM-D17) and less than 10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Specifically, the HAM-D17 evaluation revealed a 41 percent remission rate for EFFEXOR/EFFEXOR XR patients, significantly greater than that of patients receiving an SSRI (35 percent, p<0.001), or a placebo (25 percent,
'"/>

Contact: Douglas Petkus, Wyeth Pharmaceuticals
484-865-5140
Porter Novelli
19-May-2003


Page: 1 2 3 4

Related medicine news :

1. Landmark survey reveals asthma in children remains significantly out of control in the United States
2. Landmark study shows coenzyme Q10 slows progressive decline in Parkinsons disease
3. Landmark XENDOS study shows Xenical prevents or delays the development of type 2 diabetes
4. Landmark study demonstrates potential for nerve regeneration treatment of stroke
5. Landmark study results published in NEJM highlight breakthrough treatment for heart failure
6. Landmark study uncovers reasons behind recurring back injury
7. Landmark clinical trial at 22 medical centers finds implanted heart pumps lengthen and improve lives of terminally ill heart failure patients
8. Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritoneal dialysis
9. Landmark school-based social influences smoking-prevention program found not to work
10. U.S., British scientific societies honor penicillin as International Chemical Landmark
11. CODE-2*: Landmark study on the costs of type 2 diabetes in Europe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2019)... , ... September 21, 2019 , ... ... that he has been certified by the American Academy of Facial Esthetics (AAFE) ... professional medical-grade skin care products. , Dr. Patel has also been certified by ...
(Date:9/18/2019)... YORK (PRWEB) , ... September 18, 2019 , ... DOROT hosts its annual Rosh Hashanah ... from which more than 700 volunteers will be heading out to visit our seniors. , ... , The Upper East Side, at Central Synagogue 123 East 55st Street , ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... winner Meb Keflezighi and the American Heart Association (AHA)-San Diego Chapter to raise ... Heart and Stroke Walk on Saturday, September 21 in Balboa Park alongside National ...
(Date:9/17/2019)... ... September 17, 2019 , ... Dr. Jacqueline ... laser dentistry . A minimally invasive approach to gum surgery, laser dentistry ... , Laser dentistry is gentle and effective because it simply uses laser light ...
(Date:9/17/2019)... CHICAGO (PRWEB) , ... September 17, 2019 , ... ... cocktail reception fundraiser. Gather for GRIN2B will be held at Found Kitchen ... p.m. , Proceeds will help fund research on GRIN2B-Related Neurodevelopmental Disorder, a rare condition ...
Breaking Medicine News(10 mins):
(Date:9/14/2019)... MILWAUKEE (PRWEB) , ... September 13, 2019 , ... The ... voted, based on the available safety and efficacy data, to recommend approval of a ... be Palforzia, but it was previously referred to as AR101. , The FDA would ...
(Date:9/14/2019)... ... September 14, 2019 , ... CME4Life, a leading provider ... announcing its attempt at a world record “Longest Medical Lecture” on November 16, ... while earning 30 CME credits in 30 consecutive hours. ?The conference will take ...
(Date:9/12/2019)... ... September 12, 2019 , ... Stratosphere Networks will ... will take place on Monday, October 7 at Found Kitchen and Social House in ... fund research on GRIN2B-Related Neurodevelopmental Disorder. GRIN2B is a gene on the short arm ...
Breaking Medicine Technology:
Cached News: